Attached files
| file | filename |
|---|---|
| EX-99.01 - EXHIBIT 99.01 - PALISADE BIO, INC. | v351813_ex99-01.htm |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 2, 2013 (August 1, 2013)
Neuralstem, Inc.
(Exact name of registrant as specified in Charter)
| Delaware | 000-1357459 | 52-2007292 | ||
|
(State or other jurisdiction of incorporation or organization) |
(Commission File No.) | (IRS Employee Identification No.) |
9700 Great Seneca Highway,
Rockville, Maryland 20850
(Address of Principal Executive Offices)
(301) 366-4841
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Events. |
On August 1, 2013, Neuralstem, Inc. (“Company”) announced that a paper published in the journal “Cell Transplantation – The Regenerative Medicine Journal,” reported that the Company’s spinal cord-derived neural stem cells, NSI-566, improved cognitive function in rats who’d received radiation to the brain as assessed by two separate cognitive tasks. A copy of the press release is attached to this report as Exhibit 99.01.
| Item 9.01 | Financial Statement and Exhibits. |
| Exhibit Number | Description | |
| 99.01 | Press Release Dated August 1, 2013 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Issuer has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
| NEURALSTEM, INC | ||||
| By: |
/s/ I. Richard Garr |
|||
|
I. Richard Garr Chief Executive Officer |
||||
Dated: August 2, 2013
INDEX OF EXHIBITS
| Exhibit Number | Description | |
| 99.01 | Press Release Dated August 1, 2013 | |